Novo Nordisk A/S (NYSE:NVO) Shares Sold by EP Wealth Advisors LLC

EP Wealth Advisors LLC decreased its holdings in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 23.1% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 58,105 shares of the company's stock after selling 17,461 shares during the quarter. EP Wealth Advisors LLC's holdings in Novo Nordisk A/S were worth $4,998,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in the business. M. Kulyk & Associates LLC lifted its stake in Novo Nordisk A/S by 3.9% during the fourth quarter. M. Kulyk & Associates LLC now owns 3,182 shares of the company's stock valued at $274,000 after buying an additional 119 shares in the last quarter. Center for Financial Planning Inc. grew its position in Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock worth $25,000 after purchasing an additional 123 shares in the last quarter. Tradewinds Capital Management LLC raised its stake in Novo Nordisk A/S by 2.6% during the 4th quarter. Tradewinds Capital Management LLC now owns 4,984 shares of the company's stock valued at $429,000 after purchasing an additional 124 shares during the period. Exencial Wealth Advisors LLC lifted its holdings in shares of Novo Nordisk A/S by 0.5% in the fourth quarter. Exencial Wealth Advisors LLC now owns 23,094 shares of the company's stock valued at $1,987,000 after purchasing an additional 124 shares in the last quarter. Finally, Indie Asset Partners LLC boosted its position in shares of Novo Nordisk A/S by 4.2% in the fourth quarter. Indie Asset Partners LLC now owns 3,128 shares of the company's stock worth $269,000 after buying an additional 126 shares during the period. Institutional investors and hedge funds own 11.54% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on the company. Kepler Capital Markets upgraded Novo Nordisk A/S from a "hold" rating to a "buy" rating in a research report on Thursday, March 13th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. BMO Capital Markets reiterated a "market perform" rating and set a $64.00 price objective (down from $105.00) on shares of Novo Nordisk A/S in a report on Thursday, April 17th. Hsbc Global Res raised Novo Nordisk A/S to a "strong-buy" rating in a research note on Monday, April 28th. Finally, Stifel Nicolaus lowered shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating in a research report on Monday, March 3rd. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating, five have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $135.00.

Novo Nordisk A/S Trading Up 1.8 %

Shares of NYSE:NVO opened at $67.49 on Thursday. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.55 and a current ratio of 0.74. The stock's 50-day moving average is $70.14 and its 200-day moving average is $86.94. The company has a market cap of $302.88 billion, a P/E ratio of 20.51, a P/E/G ratio of 0.90 and a beta of 0.65. Novo Nordisk A/S has a 52-week low of $57.00 and a 52-week high of $148.15.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.